MTCR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 Jun 2023 @ 15:11):

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases...

Stats
Today's Volume	83 889.00
Average Volume	52 473.00
Market Cap	25.48M
EPS	$0 ( 2023-11-13 )
Last Dividend	$0.580 ( 2023-06-21 )
Next Dividend	$0 ( N/A )
P/E	-0.564
ATR14	$0.0160 (2.75%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-23	Klassen Preston	Sell	842 211	Common Stock
2023-03-23	Klassen Preston	Sell	842 211	Stock Option (right to buy)
2023-01-26	York Michael	Sell	107 054	Common Stock
2023-01-26	Klassen Preston	Sell	380 605	Common Stock
2022-12-21	Leonard Braden Michael	Buy	120 099	Common Stock

INSIDER POWER
-15.88
Last 97 transactions
Buy: 12 877 287 \| Sell: 12 262 808

Volume Correlation

Long: -0.64 (weak negative)

Short: 0.81 (strong)

Signal:(57.111) Same movement expected

Metacrine, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Metacrine, Inc. Correlation - Currency/Commodity

0.39
( neutral )

0.35
( neutral )

0.00
( neutral )

0.42
( neutral )

0.00
( neutral )

-0.03
( neutral )

Metacrine, Inc. Financials

Annual	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.40

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.40

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.436

FY	2019
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.520

Financial Reports:

No articles found.

Metacrine, Inc. Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.580 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Metacrine, Inc. Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.580	2023-06-21
Last Dividend	$0.580	2023-06-21
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.580	--
Avg. Dividend % Per Year	43.27%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-27)

$1.160 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$0.580	129.80%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.766	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.835	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	10.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	13.40	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	9.85	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.177	-1.500	7.06	-10.00	[0 - 0.6]
interestCoverageTTM	-50.81	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.120	2.00	-0.373	-0.747	[0 - 30]
freeCashFlowPerShareTTM	-1.120	2.00	-0.560	-1.120	[0 - 20]
debtEquityRatioTTM	0.246	-1.500	9.01	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-3.34	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.578

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.400	1.000	-0.141	0	[1 - 100]
returnOnEquityTTM	-0.835	2.50	-6.68	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.120	2.00	-0.373	-1.120	[0 - 30]
dividendYielPercentageTTM	99.76	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.120	2.00	-0.373	-0.747	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-0.413

Metacrine, Inc.

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.